inPractice® - Drug–Drug Interactions

Management of AIDS-Defining Cancers

Authors: David Aboulafia, MD (More Info)
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 4/9/18 (What's New)

Summary

PIs may worsen chemotherapy-related myelotoxicity^{[Bower 2004]}
Zidovudine can be associated with myelotoxicity and should be avoided during chemotherapy^{[Beumer 2014; Kaplan 2012; Rudek 2011]}
Pharmacologic boosters, ritonavir and cobicistat, are CYP3A4 inhibitors with reported and anticipated interactions with many chemotherapy agents as well as some targeted antitumor drugs^{[Alvarnas 2017; Berretta 2016; Rubinstein 2014; Beumer 2014]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Cancer